A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of zampilimab in healthy study participants.

Study Overview

• Status: Completed
• Conditions: Healthy Study Participants
• Intervention / Treatment: Drug: Zampilimab; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom
    • Up0105 001

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant must be 18 to 55 years of age inclusive, at the time of signing the Informed Consent Form (ICF)
• Study participant must be considered reliable and capable of adhering to the protocol, according to the judgment of the Investigator, and is able to communicate satisfactorily with the Investigator and comply with all clinical study requirements
• Study participant has adequate peripheral venous access
• Study participant has clinical laboratory test results within the reference ranges of the testing laboratory. Study participants with test results that are outside the specified ranges and that are deemed as clinically nonsignificant will be allowed at the discretion of the Investigator
• Study participant is of normal weight as determined by a body mass index between 18 and 32 kg/m^2, inclusive, with a body weight of at least 50 kg (male) or 45 kg (female) and no greater than 100 kg
• Study participants may be male or female
• Male participants must agree to use contraception during treatment period and for 5 months; female participants of childbearing potential must be not pregnant or breastfeeding and agree to use contraception during the treatment period and for 5 months

Exclusion Criteria:

• Study participant has any medical (acute or chronic) or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the IMP; or interfering with the interpretation of data
• Study participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) as stated in this protocol or participant has a history of moderate to severe allergic reaction to medication(s), including biologics
• Study participant has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or electrocardiogram (ECG), which, in the opinion of the Investigator, may place the participant at risk because of participation in the study
• Study participant has had major surgery (including joint surgery) within 6 months prior to the Screening Period, or has planned surgery within 6 months after IMP
• Study participant has current diagnosis or history of wound healing complications
• Study participant has a history of alcohol and/or drug abuse up to 6 months before the Screening Period
• Study participant has active neoplastic disease or history of neoplastic disease within 5 years of the Screening Period
• Study participant has an active infection during the Screening Period
• Study participant has clinical signs and symptoms consistent with coronavirus disease (COVID-19) or had a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result within the last 4 weeks prior to the Screening Period or on admission
• Study participant has had a severe course of COVID-19 that required hospitalization
• Study participant has received any prescription or nonprescription medicines, including over the counter (OTC) remedies or herbal and dietary supplements, within 14 days or 5 half-lives of the respective drug, whichever is longer, other than the occasional use of analgesics, such as paracetamol (acetaminophen) or ibuprofen, oral contraceptives, or inhaled corticosteroids for seasonal rhinitis
• Study participant has received treatment with biologic agents (such as monoclonal antibodies (mAbs) including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
• Study participant has received a vaccination within 8 weeks prior to Day 1; or intends to have a vaccination during the course of the study
• Study participant has participated in another study of a IMP (and/or an investigational device) within the previous 3 months or 5 half-lives prior to the Screening Period, whichever is longer, or is currently participating in another study of a IMP (and/or an investigational device)
• Study participant has positive serology test for hepatitis B surface antigen, hepatitis B core antibodies (both immunoglobulin G (IgG) and IgM), hepatitis C virus antibodies, or antibodies to human immunodeficiency virus type 1 and/or type 2 during the Screening Period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Zampilimab Cohorts; Participants will be randomized to receive predefined single doses of zampilimab.	Drug: Zampilimab; Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.; Other Names: UCB7858
Placebo Comparator: Placebo; Participants randomized to this arm will receive matching Placebo to maintain the blinding.	Drug: Placebo; Participants will receive matching placebo at a pre-specified time point to maintain the blinding.; Other Names: PBO

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidents of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit	A treatment-emergent adverse event (TEAE) is defined as any event not present prior to the administration of investigational medicinal product (IMP) or any unresolved event already present before administration of IMP that worsens in intensity following exposure to the treatment.	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Maximum intensity of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit	Maximum intensity across all incidents of each TEAE for each study participant	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum zampilimab serum concentration (Cmax)	Cmax: Maximum observed zampilimab serum concentration	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Time to maximum zampilimab serum concentration (tmax)	tmax: Time to maximum observed zampilimab serum concentration	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Area under the zampilimab serum concentration-time curve from time zero to last quantifiable concentration (AUC0-t)	AUC0-t: Area under the zampilimab serum concentration-time curve from time zero (Day 1) to the last quantifiable concentration	From Day 1 (Start of Treatment Period) at predefined time points to the last quantifiable concentration (up to 120 days)
Area under the zampilimab serum concentration-time curve from time zero to infinity (AUC)	AUC: Area under the zampilimab serum concentration-time curve from time 0 (Day 1) to infinity	Day 1 (Start of Treatment Period) at predefined time points (up to 120 days)
Clearance (CL) of zampilimab in serum	CL: volume of serum that is cleared from zampilimab per unit of time	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Apparent volume of distribution during terminal phase (Vz) of zampilimab	Vz: apparent volume of distribution during terminal phase	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Apparent terminal half-life (t1/2) of zampilimab	t1/2: terminal zampilimab serum half-life	From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)

Collaborators and Investigators

• Sponsor: UCB Biopharma SRL
• Investigators: Principal Investigator: UCB Cares, 001 844 599 2273 (UCB)

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2021
• Primary Completion (Actual): July 28, 2021
• Study Completion (Actual): July 28, 2021

Study Registration Dates

• First Submitted: January 8, 2021
• First Submitted That Met QC Criteria: January 8, 2021
• First Posted (Actual): January 12, 2021

Study Record Updates

• Last Update Posted (Actual): July 19, 2022
• Last Update Submitted That Met QC Criteria: July 15, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Phase 1; Healthy study participants; UCB7858; zampilimab
• Other Study ID Numbers: UP0105; 2020-004411-26 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No